Brazilian Consensus On Chagas Disease, 2015

A doença de Chagas é uma condição crônica negligenciada com elevada carga de morbimortalidade e impacto dos pontos de vista psicológico, social e econômico. Representa um importante problema de saúde pública no Brasil, com diferentes cenários regionais. Este documento traduz a sistematização das evidências que compõe o Consenso Brasileiro de Doença de Chagas. O objetivo foi sistematizar estratégias de diagnóstico, tratamento, prevenção e controle da doença de Chagas no país, de modo a refletir as evidências científicas disponíveis. Sua construção fundamentou-se na articulação e contribuição estratégica de especialistas brasileiros com conhecimento, experiência e atualização sobre diferentes aspectos da doença. Representa o resultado da estreita colaboração entre a Sociedade Brasileira de Medicina Tropical e o Ministério da Saúde. Espera-se com este documento fortalecer o desenvolvimento de ações integradas para enfrentamento da doença no país com foco em epidemiologia, gestão, atenção integral (incluindo famílias e comunidades), comunicação, informação, educação e pesquisas.25especial78

A global agenda for advancing freshwater biodiversity research

Global freshwater biodiversity is declining dramatically, and meeting the challenges of this crisis requires bold goals and the mobilisation of substantial resources. While the reasons are varied, investments in both research and conservation of freshwater biodiversity lag far behind those in the terrestrial and marine realms. Inspired by a global consultation, we identify 15 pressing priority needs, grouped into five research areas, in an effort to support informed stewardship of freshwater biodiversity. The proposed agenda aims to advance freshwater biodiversity research globally as a critical step in improving coordinated actions towards its sustainable management and conservation

2 nd Brazilian Consensus on Chagas Disease, 2015

Abstract Chagas disease is a neglected chronic condition with a high burden of morbidity and mortality. It has considerable psychological, social, and economic impacts. The disease represents a significant public health issue in Brazil, with different regional patterns. This document presents the evidence that resulted in the Brazilian Consensus on Chagas Disease. The objective was to review and standardize strategies for diagnosis, treatment, prevention, and control of Chagas disease in the country, based on the available scientific evidence. The consensus is based on the articulation and strategic contribution of renowned Brazilian experts with knowledge and experience on various aspects of the disease. It is the result of a close collaboration between the Brazilian Society of Tropical Medicine and the Ministry of Health. It is hoped that this document will strengthen the development of integrated actions against Chagas disease in the country, focusing on epidemiology, management, comprehensive care (including families and communities), communication, information, education, and research

The main determinants of diabetes mellitus vascular complications: Endothelial dysfunction and platelet hyperaggregation

Diabetes mellitus is a common disease that affects 3–5% of the general population in Italy. In some countries of northern Europe or in North America, it can even affect 6–8% of the population. Of great concern is that the number of cases of diabetes is constantly increasing, probably due to the increase in obesity and the sedentary nature of the population. According to the World Health Organization, in the year 2030 there will be 360 million people with diabetes, compared to 170 million in 2000. This has important repercussions on the lives of patients and their families, and on health systems that offer assistance to patients. In this review, we try to describe in an organized way the pathophysiological continuity between diabetes mellitus, endothelial dysfunction, and platelet hyperaggregation, highlighting the main molecular mechanisms involved and the interconnections

The Impact of Aging on Cardio and Cerebrovascular Diseases

A growing number of evidences report that aging represents the major risk factor for the development of cardio and cerebrovascular diseases. Understanding Aging from a genetic, biochemical and physiological point of view could be helpful to design a better medical approach and to elaborate the best therapeutic strategy to adopt, without neglecting all the risk factors associated with advanced age. Of course, the better way should always be understanding risk-to-benefit ratio, maintenance of independence and reduction of symptoms. Although improvements in treatment of cardiovascular diseases in the elderly population have increased the survival rate, several studies are needed to understand the best management option to improve therapeutic outcomes. The aim of this review is to give a 360° panorama on what goes on in the fragile ecosystem of elderly, why it happens and what we can do, right now, with the tools at our disposal to slow down aging, until new discoveries on aging, cardio and cerebrovascular diseases are at hand

Phase A Science Case for MAVIS -- The Multi-conjugate Adaptive-optics Visible Imager-Spectrograph for the VLT Adaptive Optics Facility

We present the Phase A Science Case for the Multi-conjugate Adaptive-optics Visible Imager-Spectrograph (MAVIS), planned for the Adaptive Optics Facility (AOF) of the Very Large Telescope (VLT). MAVIS is a general-purpose instrument for exploiting the highest possible angular resolution of any single optical telescope available in the next decade, either on Earth or in space, and with sensitivity comparable to (or better than) larger aperture facilities. MAVIS uses two deformable mirrors in addition to the deformable secondary mirror of the AOF, providing a mean V-band Strehl ratio of >10% (goal >15%) across a relatively large (30 arc second) science field. This equates to a resolution of <20mas at 550nm - comparable to the K-band diffraction limit of the next generation of extremely large telescopes, making MAVIS a genuine optical counterpart to future IR-optimised facilities like JWST and the ELT. Moreover, MAVIS will have unprecedented sky coverage for a high-order AO system, accessing at least 50% of the sky at the Galactic Pole, making MAVIS a truly general purpose facility instrument. As such, MAVIS will have both a Nyquist-sampled imager (30x30 arcsec field), and a powerful integral field spectrograph with multiple spatial and spectral modes spanning 370-1000nm. This science case presents a distilled set of thematically linked science cases drawn from the MAVIS White Papers (www.mavis-ao.org/whitepapers), selected to illustrate the driving requirements of the instrument resulting from the recent MAVIS Phase A study

Phase A Science Case for MAVIS -- The Multi-conjugate Adaptive-optics Visible Imager-Spectrograph for the VLT Adaptive Optics Facility

141 pages, 79 figures, 10Mb. Modified version of the Phase A Science Case submitted to ESO in April 2020 as part of the MAVIS Phase A design study. Full resolution version available upon requestWe present the Phase A Science Case for the Multi-conjugate Adaptive-optics Visible Imager-Spectrograph (MAVIS), planned for the Adaptive Optics Facility (AOF) of the Very Large Telescope (VLT). MAVIS is a general-purpose instrument for exploiting the highest possible angular resolution of any single optical telescope available in the next decade, either on Earth or in space, and with sensitivity comparable to (or better than) larger aperture facilities. MAVIS uses two deformable mirrors in addition to the deformable secondary mirror of the AOF, providing a mean V-band Strehl ratio of >10% (goal >15%) across a relatively large (30 arc second) science field. This equates to a resolution of <20mas at 550nm - comparable to the K-band diffraction limit of the next generation of extremely large telescopes, making MAVIS a genuine optical counterpart to future IR-optimised facilities like JWST and the ELT. Moreover, MAVIS will have unprecedented sky coverage for a high-order AO system, accessing at least 50% of the sky at the Galactic Pole, making MAVIS a truly general purpose facility instrument. As such, MAVIS will have both a Nyquist-sampled imager (30x30 arcsec field), and a powerful integral field spectrograph with multiple spatial and spectral modes spanning 370-1000nm. This science case presents a distilled set of thematically linked science cases drawn from the MAVIS White Papers (www.mavis-ao.org/whitepapers), selected to illustrate the driving requirements of the instrument resulting from the recent MAVIS Phase A study